A phase II clinical trial to analyze olaparib response in patients with <i>BRCA1</i> and/or <i>BRCA</i>2 promoter methylation with advanced breast cancer (GEICAM/2015-06 COMETA-Breast study).
Juan de la Haba-Rodríguez, Ángel Guerrero‐Zotano, José Alejandro Pérez Fidalgo, Santiago González Santiago, Montserrat Muñoz, Raquel Andrés, Cristina Cruz Zambrano, Sebastian Moran Salama, Sara López‐Tarruella, Vanesa Garcı́a, Sònia Servitja, Mireia Melé, Sonia Alonso Soler, Bárbara Adamo, M.J. Escudero, N Martin, Susana Bezares, Rosalía Caballero, Manel Esteller, Federico Rojo (2018). A phase II clinical trial to analyze olaparib response in patients with <i>BRCA1</i> and/or <i>BRCA</i>2 promoter methylation with advanced breast cancer (GEICAM/2015-06 COMETA-Breast study).. , 36(15_suppl), DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.tps1114.
